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Numerous viruses of the Flaviviridae family, including dengue, yellow fever, Japanese encephalitis, and West Nile, cause significant disease in
humans and animals. The structure and function of the molecular components of the flavivirus envelope are therefore of significant interest. To our
knowledge, a membrane (M) protein mutation which affects the pH at which flavivirus particles are inactivated in vitro has never been reported.
Here we show that substitution of proline for glutamine at residue M5 (MQ5P) of a Japanese encephalitis–yellow fever chimera (ChimeriVax-JE)
increases its acid sensitivity in vitro by 0.3 pH units (i.e., increases the pH at which virus titer is reduced by 50% from 6.08 to 6.38). In addition,
growth kinetics of this mutant virus are accelerated in Vero cells, while neurovirulence and neuroinvasiveness measured in a mouse model are
unaffected. A possible interpretation of these observations is that M can modulate the envelope (E) protein function during cell infection.
© 2007 Elsevier Inc. All rights reserved.Keywords: Acid inactivation; Membrane protein; Premembrane protein; Envelope protein; Chimera; Japanese encephalitis; Yellow fever; ChimeriVax; Vaccine;
Membrane fusionIntroduction
Flaviviruses comprise numerous viral species, including
dengue, yellow fever, Japanese encephalitis, and West Nile
viruses, which cause significant disease in humans and animals
(Burke and Monath, 2001; Pugachev et al., 2005). A better
understanding of the structure and function of the flavivirus
envelope proteins is therefore of significant interest because it
may lead to new drugs and vaccines.
The flavivirus genome is a single, positive strand of RNA
encoding three structural proteins and seven non-structural
proteins. Two of the structural proteins are transmembrane
proteins designated E (envelope) and prM (premembrane)
which are cotranslationally incorporated into the immature viral
membrane. The latter, after exposure to low pH in the infected⁎ Corresponding author. Fax: +1 617 494 1741.
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doi:10.1016/j.virol.2007.01.008cell's secretory pathway, is processed by cellular furin to yield
mature viral particles containing E and M (Stadler et al., 1997).
Most studies of flavivirus membrane fusion mechanisms
have focused on E, which contains the viral fusion peptide,
putative receptor binding sites, and antigenic determinants
involved in induction of neutralizing antibodies in the host. This
protein is approximately 500 amino acids in length, while M is
75 amino acids long. The three-dimensional structure of E has
been solved under a variety of conditions, using both X-ray
crystallography (Modis et al., 2003, 2004; Rey et al., 1995) and
cryo-electron microscopy (Ferlenghi et al., 2001; Mukhopad-
hyay et al., 2003; Zhang et al., 2003a, 2003b, 2004). This
growing body of knowledge has yielded a dynamic model of
membrane fusion wherein E undergoes low-pH-induced qua-
ternary and tertiary structure changes leading to the burial of its
hydrophobic fusion peptide into the cell membrane which is then
pulled toward the viral membrane surface to achieve membrane
fusion (Kielian, 2006; Mukhopadhyay et al., 2005; Stiasny and
Heinz, 2006). Numerous mutations in E are known to alter the
pH triggering these conformational changes (Table 1).
Table 1
Shifts in pH threshold of inactivation or of fusion of E protein mutants
Virus and substitution pH shift detected
(difference) a
Reference
DEN-2 EH317Q 6.77 to 6.55 (0.22) (Goncalvez
et al., 2004)DEN-2 EG106V 6.77 to 6.41 (0.36)
TBE EG368R 6.25 to 6.7 (0.45) (Holzmann
et al., 1997)TBE ED181Y 6.25 to 6.4 (0.15)
TBE EA123L 6.25 to 6.4 (0.15)
TBE EL171E 6.3 to 5.9 (0.4) (Guirakhoo
et al., 1991)
DEN-1 EF279S 6.4 to ∼6.7 (0.3) (Beasley and
Aaskov, 2001)DEN-1 ET293I 6.4 to ∼6.6 (0.2)
MVE ES277V 6.6 to 6.8 (0.2) (Hurrelbrink and
McMinn, 2001)MVE ES277P 6.6 to 6.8 (0.2)
DEN-3 EF191V EK202R
EI268V/I/S EF277S EE401L ET403I
(0.6 to 1.0) (Lee et al., 1997)
EA54E (0.2)
ET155A, ET155M (0.4)
DEN-2 EN153D 6.85 to 7.5 (0.65) (Guirakhoo
et al., 1993)
a Shift in pH of inactivation or fusion as reported in cited reference, or
estimated by inspection of data reported; difference between wild type and
mutant shown in parenthesis.
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and function. A close association between the prM and E
proteins has been demonstrated biochemically (Guirakhoo et al.,
1991, 1992; Konishi and Mason, 1993) and by biophysical
methods (Zhang et al., 2003a, 2003b). Study of immature
particles, isolated by preventing the low-pH-dependent furin
cleavage of prM, showed that they were incapable of fusion with
cell membranes even after acid treatment and that prM hides
certain E epitopes (Guirakhoo et al., 1991, 1992). Immature
particle structures have also been obtained in which prM is
partially resolved (Zhang et al., 2003b, 2004). The function of
prM in the viral lifecycle is interpreted as that of a chaperone,
preventing E from prematurely undergoing conformational
changes that lead to fusion while viral particles are transiting
from the endoplasmic reticulum through the Golgi to the cell
surface (Lindenbach and Rice, 2001). Following cleavage of
prM into pr andM polypeptides, the viral particle rearranges into
its mature form in which the E monomers organize into dimers.
All but the first 20 amino acids of M can be seen in cryo-electron
microscopy of mature dengue virus particles (Zhang et al.,
2003a). Very little information is available concerning M
function in mature viral particles. To our knowledge, M
mutations have never been reported to affect the pH at which
acid inactivation of viral particles occurs.
Here we present such a mutation and discuss the possibility
that the M protein of Japanese encephalitis virus modulates E
protein function. Specifically, we show that a mutation in the M
gene of ChimeriVax-JE (CV-JE) leads to a significant change in
the pH of inactivation of the virus and to accelerated growthkinetics. CV-JE virus is a chimeric, live attenuated vaccine
comprising the prM and E genes of Japanese encephalitis SA14-
14-2 and the C and non-structural genes of the molecular clone
of yellow fever vaccine YF17D (Chambers et al., 1999; Monath
et al., 1999). This vaccine was shown to be genetically stable
(Guirakhoo et al., 1999), safe, and effective in phase I and II
clinical trials for prevention of Japanese encephalitis infection
(Monath et al., 2003; Pugachev et al., 2004) and is currently
undergoing phase III evaluation.
Results
As discussed previously (Guirakhoo et al., 1999), in vivo
passage of CV-JE in mouse brains caused no change in the
phenotype of the vaccine and caused no reversion of the
attenuating residues present in the E protein. A single
substitution at prM amino acid 97, corresponding to M residue
5, was found by DNA sequencing after six brain–brain passages
of the virus in two independent mouse experiments. Interest-
ingly, this substitution of P for Q at position M5 (henceforth
referred to as MQ5P) was observed when screening for viruses
with accelerated growth kinetics in vitro (C. Maier, unpublished
results).
To better understand the function of residue M5, three amino
acid substitutions were engineered in CV-JE by site-directed
mutagenesis using standard methods, as described previously
(Arroyo et al., 2001). The originally observed amino acid change
MQ5P as well as substitutions to S (MQ5S) and I (MQ5I) were
introduced into the prM gene, and the resulting mutant DNA
clones were used as templates for the production of infectious
genomic RNA. A control corresponding to the parent (i.e., non-
mutant) virus, CV-JE MQ5, was reconstructed in parallel.
Transfection of these altered RNA genomes in Vero cells led
to the appearance of viable virus in two of the three samples;
mutant MQ5I did not produce viable virus, as judged by the
absence of cytopathic effects (cpe) in transfected cells and lack
of plaque-forming units (pfu) in plaque assays of the transfected
cell culture medium (Fig. 1A, MQ5I titer less than detection limit
of 103 pfu/ml). Sequencing of the mutation-bearing fragment of
the MQ5I mutant viral cDNA genome in plasmid pYF5′3′IV/JE
SA14-14-2/Q5I confirmed the absence of unwanted mutations;
repeated transfection of the corresponding mutant genomic
RNA did not lead to cytopathic effects or to detectable plaque
counts, even after a second passage (data not shown; titer <102
pfu/ml). Also, reverse transcription PCR (RT-PCR) of first or
second passage supernatant yielded a band of the expected size
for each of CV-JE, MQ5S, and MQ5P, but not MQ5I (data not
shown).
Growth kinetics of the mutant viruses were compared with
the parent virus. Vero cells were infected at a multiplicity of
infection (moi) of 0.01 pfu/cell, and samples of culture
supernatant were taken daily. Viral titers were then determined
by standard plaque assay for each time point, as shown in Fig.
1B. Consistent with the mutant selected in vitro for rapid
growth, engineered mutant MQ5P displays accelerated replica-
tion leading to a mean peak titer of 2.9×107 pfu/ml in 3 days,
versus a titer of 1.3×107 pfu/ml for the parent CV-JE virus
Fig. 2. Effect of amino acid substitution MQ5P on the pH threshold of
inactivation of CV-JE virus. Virus samples were incubated in MEM adjusted to
different pH values using MES for 10 min at room temperature, neutralized with
FBS and added to a monolayer of Vero cells (∼50 pfu/well input titer). (A) Data
from a single experiment are shown in which the plaque count is plotted (mean
of duplicate wells, error bars are standard error of the mean) as a function of the
pH during inactivation. Mutants MQ5P, MQ5S, and the parent control (MQ5) are
shown. (B) Data points represent the means of the plaque counts normalized to
the highest count for each data series as a function of the pH of incubation. In
addition to the mutants shown in panel A, mutant “clone E,” in which the
substitution MQ5P arose spontaneously, is also plotted. Results are from 2 (MQ5,
MQ5P) or 3 (clone E, M5QS) separate experiments. Note how MQ5P viruses are
completely inactivated at pH 6.2, while parent virus and MQ5S are nearly
unaffected. Error bars indicate the standard error of the mean.
Fig. 1. Effect of amino acid substitutions at residue 5 of M protein on CV-JE
viability and replication. (A) Following transfection of Vero cells with mutant
Q5P, Q5S, Q5I, or CV-JE parent control (Q5) RNA, samples of culture
supernatant were harvested on day 6, and titers determined by plaque assay. (B)
In duplicate experiments, Vero cells were infected with passage 2 virus (moi of
0.01 pfu/cell), and samples were taken at the indicated times. Plaque assays were
performed to measure virus titers. Data points are means of duplicate plaque
counts for each experiment, and error bars represent the standard error of the
mean (N=4=2 experiments×2 plaque counts for each experiment).
Table 2
pH threshold of inactivation (pHi) of parent and mutant CV-JE virus
Virus pHi
CV-JE MQ5 (parent control) 6.08
Mutant MQ5S 6.06
Mutant MQ5P 6.38
CV-JE clone E (Q5P) 6.39
470 C.C. Maier et al. / Virology 362 (2007) 468–4741 day later. Mutant MQ5S grew to a lower peak titer of 5.5×10
6
pfu/ml on day 4.
Plaque morphology of these mutants was also examined. The
transfection supernatant, designated “passage 1” (P1), was used
to infect a fresh monolayer, and the resulting second passage
(P2) supernatant samples were harvested on the day of peak titer
(day 3 or 4, depending on the mutant). Plaque assays were
carried out on P2 samples using a neutral red-containing
agarose overlay. Mutant MQ5P typically displayed a larger
median plaque size of ∼2 mm compared to the parent virus
(∼1 mm) or the Q5S mutant (∼0.5 mm); data not shown.
To better understand the molecular basis for these
phenotypic changes, the effect of pH on envelope function of
parent and mutant viruses was investigated. Initial attempts to
do fusion-from-within assays were unsuccessful. While dengue
virus fuses C6/36 cells effectively (Guirakhoo et al., 1993), our
chimeric viruses, including dengue chimeras, yield little or nofusion in this assay (data not shown). As an alternative, we
employed a pH-inactivation assay relying on treatment of virus
samples for 10 min in medium acidified to varying extents
using MES. This method mimics the low-pH-induced con-
formational rearrangement in the envelope during fusion. In the
absence of cell membrane, acid treatment results in loss of virus
infectivity. Following incubation, the virus suspension was
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for the lowest pH sample) and used to infect Vero cell
monolayer to yield plaques. As shown in Fig. 2A for one
representative experiment, input plaque titer decreases in a
sigmoidal fashion as pH is decreased. Two (CV-JE MQ5, MQ5P)
or three (clone E, MQ5S) such experiments were carried out, the
plaque counts normalized to 1, and means±standard error of
the mean were plotted in Fig. 2B. In this study, the pH at which
input virus titer is reduced by 50% is considered the pH
threshold of inactivation, or pHi. Note that MQ5P viruses are
completely inactivated at pH 6.2, while parent virus and MQ5S
are nearly unaffected.
Table 2 shows the calculated pHi for the curves shown in Fig.
2 as well as for clone E (MQ5P mutant selected in vitro). The pHi
of mutant MQ5P is increased by 0.3 pH units, from 6.08 to 6.38,
relative to the parent control or mutant MQ5S. Statistical analysis
indicates that the pHi of MQ5P and clone E are significantly
different from the pHi of MQ5S or of control virus CV-JE MQ5
(95% confidence intervals do not overlap, see Materials and
methods).
To determine whether mutations at the M5 residue had any
effect on the biological phenotype of CV-JE in vivo,
neurovirulence (NV) of the mutants was compared with
parent CV-JE in both adult and infant mice. Groups of five 8-
week-old mice were inoculated intracerebrally (i.c.) with at
least 1.6×104 pfu of either CV-JE clone A (parent), CV-JE
clone E (Q5P mutant selected in vitro), mutant MQ5S, mutant
MQ5P, or CV-JE MQ5 parent control. A positive control group
received 4.0×103 pfu of yellow fever 17D vaccine virus (YF-
VAX) by the same route. Only mice infected with YF-VAX
died (data not shown).
Neurovirulence in more sensitive 6-day-old mice was also
determined. For this experiment, infant mice (11 per group)
received 103, 102, or 10 pfu i.c. of the following three viruses:
CV-JE clone A (parent), CV-JE clone E (Q5P mutant selected
in vitro), and mutant MQ5S. In the positive control group, each
of 11 animals received 1.6×102 pfu of YF-VAX i.c. In Fig. 3,
survival curves for the groups that received 103 pfu are
compared with the YF-VAX control group. Statistical analysisFig. 3. Effect of substitutions at M protein residue Q5 on neurovirulence of CV-
JE in infant mice. Groups of eleven 6-day-old ICR mice were inoculated i.c.
with 103 pfu of CV-JE clone A (parental Q at position 5), clone E (mutant Q5P),
mutant Q5S, or 1.6×102 pfu of YF-VAX. Percent survival is plotted as a
function of time in days post-inoculation. There is no statistically significant
difference between clone A and E (P=0.61), or between Q5S and clone E
(P=0.30) as determined by a logrank test.of these curves (logrank test) indicates that there is no
statistically significant difference between parent and mutant
CV-JE. No deaths were observed in the 10 pfu groups, and
only 1 death in the 102 pfu dose range in the CV-JE clone E
(Q5P) group.
Neuroinvasiveness of clone E was investigated using the
BALB/c mouse model of Hall et al. (1999). While the positive
control virus (wild type flavivirus Kunjin) induced pathogenic
effects, none was observed in the clone E group (K. Pugachev,
unpublished; data not shown).
Discussion
Mutagenesis at MQ5 causes significant effects on virus
viability (Fig. 1A, virus MQ5I) and accelerated growth kinetics
(Fig. 1B, virus MQ5P). The MQ5P mutation also increases plaque
size in Vero cells. Thus, virus MQ5P appears to have a selective
advantage when grown in vitro and upon brain-to-brain passage
in live mice (Guirakhoo et al., 1999). Despite its enhanced
replication rate, the mutation does not affect the attenuated
phenotype of the chimeric vaccine virus (Fig. 3), consistent with
past observations (Guirakhoo et al., 1999).
Remarkably, the same mutation (MQ5P) also renders the virus
more sensitive to acid inactivation than the parent chimeric
virus. The observed shift of 0.3 pH units, from 6.08 for the
parent CV-JE to 6.38 for the mutant MQ5P (Fig. 2 and Table 2),
is larger than many pH threshold changes caused by E protein
mutations (Table 1).
Acid inactivation is believed to take place when E dimers
in the mature virion are irreversibly triggered to form trimers
in the absence of cell membranes capable of fusing with the
virus. The structural data of Zhang et al. (2003a) suggest that
the N-terminal 20 residues of the M polypeptide – including
MQ5 – could make significant contacts with the E dimer in
mature dengue 2 flavivirus particles. However, given the
ability of purified TBEV E protein to transition from dimers to
trimers in vitro (Stiasny et al., 2004), the M protein has been
considered unnecessary for the conformational changes in the
envelope to take place. Our data suggest that, in whole viral
particles, M could help stabilize E dimers via protein–protein
interactions at neutral pH, and protonation of M residues
caused by lower pH could then destabilize the E dimer,
facilitating formation of the trimer. In the MQ5P mutant, the
M–E protein interaction might be altered in such a way that
the E dimer is less stabilized so that the pH at which E trimer
formation occurs is increased. Because the E protein dimer-to-
trimer transition is a prerequisite for fusion (Mukhopadhyay et
al., 2005), it is possible that M plays a role in regulating the
fusion process. This could be demonstrated experimentally by
showing a change in the pH threshold of fusion, which is not
addressed in our acid inactivation experiments.
A higher pH threshold of fusion for the mutant MQ5P virus
might explain its accelerated replication phenotype. As part
of the infection process, Japanese encephalitis and related
flaviviruses are endocytosed via the clathrin-dependent path-
way (Chu et al., 2006; Nawa et al., 2003), and subsequent
acidification of endocytic vesicles is thought to mediate
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become progressively more acidic as they travel from the cell
membrane towards the deeper lysosomes (Lodish et al., 2000),
membrane fusion of the mutant virus and delivery of its genome
into the cell may occur earlier (i.e., at a higher pH) than for the
parental virus, thereby enabling the mutant to replicate more
rapidly.
Other M residue substitutions may also cause pH threshold
changes. Amino acid MQ5 is only two residues away from a
histidine at position 7 (identical to His99 in prM of JE) which
is the only strictly conserved histidine in a phylogeny of 22
different flavivirus M proteins (see, for example, Figure 9 in
Lin and Wu, 2005). The pKa of histidine is quite close to the
pH threshold of fusion of most flaviviruses (between 6 and
7), and its exact value may be modulated by the
microenvironment provided by nearby M residues as well
as proximal E amino acids. Thus, it is possible that
substitutions at residue 5 affect the pKa of residue H7,
thereby changing the acid inactivation threshold of the CV-JE
mutant MQ5P. Lin and colleagues have shown a role of
prMH99 in the formation of prM–E complexes in insect cells
(Lin and Wu, 2005) consistent with this residue forming
important contacts with the E protein. However, their data
indicate a role for residue prMH99 in prM–E folding and
secretion, which may be sufficient to explain its strict
phylogenetic conservation.
In conclusion, given our observations and the reports of
other M mutations apparently affecting virus infectivity (e.g.,
dengue 2/MH39Y (Pryor et al., 2004), and yellow fever/MA279′
(polyprotein numbering) (Op De Beeck et al., 2003)), it
seems plausible that the M protein can modulate E protein
function in mature virions and influence the early events of
cell infection. Further investigation of M protein's role during
fusion may provide a more accurate picture of this step in the
flavivirus life cycle, with potential implications for the
treatment and prevention of flaviviral infections.
Materials and methods
Cells and viruses
Vero cells, strain O-Vero, were obtained from the Acambis
cell culture facility. They were used for transfection of chimeric
viruses and other assays (plaque assay, indirect fusion assay,
growth kinetics).
CV-JE mutants MQ5P, MQ5S, and MQ5I were generated by
site-directed mutagenesis (see below) and amplified in two
static passages on Vero cells. A parent control CV-JE Q5 was
also reconstructed in parallel and amplified in two static
passages on Vero cells. CV-JE clone E P7 (Q5P mutant
selected in vitro) was isolated after plaque purification and
amplification of fast-growing clones. CV-JE clone A non-
mutant parent (similar to CV-JE Q5) was produced by plaque
purification and two amplification passages in static Vero cell
culture. Commercial YF 17D vaccine (YF-VAX) was
purchased from Sanofi-Pasteur (Swiftwater, PA) and used
unpassaged.Site-directed mutagenesis
The CV-JE genome is encoded by plasmids pYF5′3′IV/JE
SA14-14-2 and pYFM5.2/JE SA14-14-2, as previously
described (Chambers et al., 1999; Guirakhoo et al., 1999).
To generate viruses containing single-site amino acid changes
at position MQ5 (i.e., Q at residue 5 of JE M protein),
plasmid pYF5′3′IV/JE SA14-14-2 was modified by replacing
a NheI–NotI restriction fragment with overlap PCR products
containing one of the following amino acid changes: MQ5P
(proline substitution), MQ5S (serine substitution), or MQ5I
(isoleucine substitution). Mutagenic oligonucleotides were
synthesized by Invitrogen Life technologies (Carlsbad, CA).
Sequences of all resulting plasmids were confirmed by
sequencing of the prME region to verify the presence of the
engineered mutation and absence of any other mutations.
Full-length cDNA templates were assembled by in vitro
ligation using T4 DNA ligase (Roche Applied Science,
Indianapolis, IN) of gel-purified NheI–BspEI restriction
fragments of mutated pYF5′3′IV/JE SA14-14-2/M5 and
pYFM5.2/JE SA14-14-2 (Chambers et al., 1999). Ligated,
full-length cDNA was linearized with XhoI and used as a
template for in vitro transcription done using the AmpliCap
SP6 kit (Epicentre, Madison, WI). Transfection of Vero cells
with RNA transcripts was performed with Lipofectamine
(Invitrogen, Carlsbad, CA). Supernatant containing virus was
harvested when cpe was observed (generally at day 6 for the
first passage, and day 3 or 4 for the second passage) and
clarified by low-speed centrifugation. FBS (HyClone, Logan,
UT) (50% by volume, final concentration) was added as a
stabilizer, and 1/7 of the volume of harvested supernatant was
used for another virus amplification on Vero cells. The
recovered viruses (P2) were titrated by plaque assay in Vero
cells as described (see below).
Plaque assays
Virus titers in harvested tissue culture supernatants were
determined by plaque assay on Vero cells. Undiluted and
serial 10-fold dilutions of supernatant in minimal essential
medium (MEM) containing 10% heat-inactivated FBS
(HyClone, Logan, UT), 100 units/ml of penicillin G
(Sigma, St. Louis, MO), 0.1 mg/ml of streptomycin sulfate
(Sigma), 0.25 μg/ml of Amphotericin B (Sigma), and 2 mM
of L-Glutamine (Sigma) were inoculated (0.1 ml) into
duplicate wells of 12-well tissue culture plates containing
monolayer cultures of Vero cells. After 1 h of adsorption at
37 °C, wells were overlaid with nutrient agarose (0.6%
agarose (Sigma) containing 5% FBS (HyClone), 100 units/ml
of penicillin G (Sigma), 0.1 mg/ml of streptomycin sulfate
(Sigma), 0.25 μg/ml of Amphotericin B (Sigma), 2 mM of L-
Glutamine (Sigma), sodium bicarbonate solution 0.20%
(Sigma)) in Eagle's MEM (Sigma) followed on day 4 with
a second overlay containing 0.1 g/l neutral red in solution
(Sigma). Twenty-four hours later, monolayers were fixed with
10% formalin (Sigma), plates were dried, and plaques were
counted on each plate.
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Vero cells were grown to confluence in T25 flasks with
Eagle's minimal medium (Invitrogen) supplemented with 10%
FBS (HyClone), 100 units/ml of penicillin G (Sigma), 0.1 mg/
ml of streptomycin sulfate (Sigma), 0.25 μg/ml of Amphotericin
B (Sigma), and 2 mM of L-Glutamine (Sigma). The cells were
infected at an moi of 0.01 with CV-JE clone A P7 PMS
(parent), CV-JE clone E (Q5P mutant selected in vitro), CV-JE
mutant Q5P (P2), CV-JE mutant Q5S (P2), and CV-JE Q5
(reconstructed parent control). After adsorption at 37 °C for
1 h, growth medium was added and flasks were returned to
the CO2 incubator. Samples of virus-containing supernatants
were taken daily for 7 days, brought to 50% FBS by volume,
and stored at −70 °C. Virus titers were determined by plaque
assay.
Acid inactivation assay
Virus suspensions (100 μl of 104 pfu/ml aliquots) were mixed
with 900 μl of pH-adjusted growth media. The pH of Eagle's
minimal medium (Sigma), supplemented with 10% FBS
(HyClone), 100 units/ml of penicillin G (Sigma), 0.1 mg/ml of
streptomycin sulfate (Sigma), 0.25 μg/ml of Amphotericin B
(Sigma), 2 mM of L-Glutamine (Sigma), and sodium bicarbonate
solution 0.20% (Sigma), was adjusted using a pHmeter to values
ranging from 6.8 to 5.6 by adding varying amounts of 1 MMES
(2-morpholinoethanesulfonic acid; Sigma). After a 10-minute
incubation at room temperature, the virus samples were returned
to pH∼7.2 by adding 1ml of FBS (HyClone), resulting in a final
volume of 2 ml (1 ml of virus suspension+1 ml of FBS). In
addition to FBS, 30 μl of sodium bicarbonate 7.5% (Sigma) was
added to the samples which had been incubated at pH 6.0 or 5.8,
and 50 μl of sodium bicarbonate 7.5% was added to the samples
incubated at pH 5.6. Then, 0.1 ml of each sample was added to
Vero monolayers in duplicate wells of 6-well plates to determine
virus titers by plaque assay.
Pfu counts were normalized to the highest pfu count for
each data series and plotted as a function of the pH of in-
cubation. The results were analyzed with GraphPad Prism
v.4.00 (GraphPad software, San Diego, CA). Sigmoidal dose
response curves were fitted to the data by allowing variable
slopes and setting Bottom >0.0 and Top <1.0 as constraints.
The sigmoidal curve fits gave an average R2 value of 0.91.
Log10EC50 values, corresponding to the pHi reported herein,
were calculated by the software, including 95% confidence
intervals which were: 6.077 to 6.083 (CV-JEMQ5 parent), 6.047
to 6.075 (MQ5S), 6.381 to 6.383 (MQ5P), and 6.386 to 6.388 (CV-
JE clone E).
Neurovirulence
All studies were performed according to an Institutional
Animal Care and Use Committee-approved protocol in
accordance with the USDA Animal Welfare Act (9 CFR parts
1 to 3) and the Guide for Care and Use of Laboratory Animals
(NIH, 1998).Neurovirulence (NV) of mutants was compared with parent
CV-JE, both in adult and infant mice. Adult (8 weeks old) ICR
mice (Taconic, Germantown, NY) were inoculated by the i.c.
route with one dilution of eachCV-JE virus (at least 1.6×104 pfu)
or 4.0×103 pfu of YF-VAX. Themice were observed for 21 days
and mortality was recorded. The virus concentration adminis-
tered to each group of animals was determined by back titration
of inocula in a plaque assay on Vero cells.
To determine NV phenotype in suckling mice, pregnant ICR
mice were purchased from Taconic (Germantown, NY) and
were observed through parturition in order to obtain litters of
suckling mice of an exact age. Suckling mice from multiple
litters born within a 72-hour interval were pooled and randomly
redistributed to mothers in groups of 11 mice. Groups of mice
were inoculated at the average age of 6 days by the i.c. route
with 103, 102, or 10 pfu of each CV-JE variant, or 1.6×102 pfu
of YF-VAX. The mice were observed for 21 days for signs of
illness, and mortality was recorded. The virus concentration
administered to each group of animals was determined by back
titration of inocula in a plaque assay on Vero cells. The survival
data were analyzed using GraphPad Prism v.4.00 (GraphPad
software). A logrank test was performed using default settings.
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